Since VCP inhibitors were designed to enhance proteotoxic stress in tumor cells and are likely to have diverse effects because of the many intracellular functions of VCP, optimization of VCP inhibitors or development of drugs to safely target either the EMC3 or VCP pathways and/or their targeted delivery to AT2 cells may make their clinical translation into ILD treatment possible. Here, VCP is linked to interstitial lung disease.